During the corresponding time, Nevro Corp saw a revenue deteriorated by -9.01 % year on year, sequentially revenue grew by 9.63 %. While revenue at the Nevro Corp 's corporate clients
The company provides products for physicians treating patients with chronic low back and leg pain, particularly pain originating in the sacroiliac (SI) joint, which affects an estimated 15% to 30% of such patients. Its product portfolio includes Nevro1™, NevroFix™, and NevroPro™ SI joint products. The company serves both U.S. and international markets, with the U.S. accounting for approximately 80% of the global spinal cord stimulation (SCS) therapy market, estimated at $2.4 billion in 2023. It focuses on the trunk-and-limb chronic pain market, which has about 11% penetration in the U.S., and seeks to expand the SCS market by addressing other pain-related indications such as painful diabetic neuropathy (PDN) and nonsurgical back pain (NSBP). The company utilizes its 10 kHz Therapy and HFX product platform to increase market share and grow the market amid competition from alternative minimally invasive spine procedures.
Nevro’s Comment on Sales, Marketing and Customers
The company provides products for physicians treating patients with chronic low back and leg pain, particularly pain originating in the sacroiliac (SI) joint, which affects an estimated 15% to 30% of such patients. Its product portfolio includes Nevro1™, NevroFix™, and NevroPro™ SI joint products. The company serves both U.S. and international markets, with the U.S. accounting for approximately 80% of the global spinal cord stimulation (SCS) therapy market, estimated at $2.4 billion in 2023. It focuses on the trunk-and-limb chronic pain market, which has about 11% penetration in the U.S., and seeks to expand the SCS market by addressing other pain-related indications such as painful diabetic neuropathy (PDN) and nonsurgical back pain (NSBP). The company utilizes its 10 kHz Therapy and HFX product platform to increase market share and grow the market amid competition from alternative minimally invasive spine procedures.
Sources:
Nevro Corp’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Nevro Corp’s corporate clients.
For your research, we’ve provided 9 tables on Nevro Corp corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
86.84 %